secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001104659-22-125317
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada licenses DM1 program to Vertex for $224M upfront, $26M equity, up to $485M milestones
--------------------------------------------------------------------------------

- Upfront payment of ~$224M plus $26M equity investment; potential milestones up to $485M and tiered mid-to-high single-digit royalties on net sales.
- Vertex gets exclusive worldwide license to ENTR-701 (late-stage preclinical) and other EEV-based DM1 candidates under 4-year research collaboration.
- Entrada will continue pre-clinical work funded by Vertex; Vertex handles global development, manufacturing, commercialization.
- Deal subject to HSR antitrust clearance; proceeds extend Entrada's cash runway into H2 2025.
- Vertex agrees to purchase 1,618,613 shares at $16.26/share (105% of VWAP) in private placement; 2-year lockup with partial release after 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922125317/0001104659-22-125317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922125317/tm2232230d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-125317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer